CounterCOVID study reaches 50% recruitment milestone

Exvastat is pleased to announce the the CounterCOVID trial of oral imatinib in Severe COVID-19 infection (previously announced here) has reached the milestone of 50% recruitment into the 386-patient study. The full details of the study protocol are to be found here: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001236-10/NL